A new highly androgen specific yeast biosensor, enabling optimisation of (Q)SAR model approaches

Journal of Steroid Biochemistry and Molecular Biology

Volumn 108, Issue 1-2, 2008, Pages 121-131

  Bovee, Toine F H ^a   Lommerse, Jos P M ^b   Peijnenburg, Ad A C M ^a   Fernandes, Elsa Antunes ^a   Nielen, Michel W F ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b NV ORGANON   (Netherlands)

Author keywords

Androgen receptor; Biosensor; Crosstalk; Green fluorescent protein; Isomers; Metabolism; QSAR modelling; Steroids

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CORTICOSTERONE; DEXAMETHASONE; DIETHYLSTILBESTROL; ENHANCED GREEN FLUORESCENT PROTEIN; ESTRADIOL; ESTROGEN RECEPTOR; ESTRONE; ETHINYLESTRADIOL; GLUCOCORTICOID RECEPTOR; NANDROLONE; TETRAHYDROGESTRINONE;

ARTICLE; BIOSENSOR; HYDROGEN BOND; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SACCHAROMYCES CEREVISIAE; YEAST CELL;

ANDROGENS; BIOSENSING TECHNIQUES; GREEN FLUORESCENT PROTEINS; HUMANS; LIGANDS; MODELS, BIOLOGICAL; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, ANDROGEN; RECOMBINANT FUSION PROTEINS; SUBSTRATE SPECIFICITY; TRANSFECTION; YEASTS;

SACCHAROMYCES CEREVISIAE;

EID: 38649124299     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2007.05.035     Document Type: Article

References (35)

1. Allen A., and Doisy E.A. An ovarian hormone. Preliminary report on its location, extraction and partial purification and action in test animals. J. Am. Med. Assoc. 81 (1923) 819-821
2. Herschberger L.G., Shiply E.G., and Meyer R.K. Myotrophic activity of 19-nortestosterone and other steroids determined by modified levator and muscle method. Proc. Soc. Exp. Biol. Med. 83 (1953) 175-180
3. Witters H.E., Vangenechten C., and Berckmans P. Detection of estrogenic activity in Flemish surface waters using an in vitro recombinant assay with yeast cells. Water Sci. Technol. 43 (2001) 117-123
4. Bovee T.F.H., Bor G., Heskamp H.H., Hoogenboom L.A.P., and Nielen M.W.F. Validation and application of a robust yeast estrogen bioassay for the screening of estrogenic activity in animal feed. Food Add. Contam. 23 (2006) 556-568
5. Haelens A., Verrijdt G., Callewaert L., Christiaens V., Schauwaers K., Peeters B., Rombauts W., and Claessens F. DNA recognition by the androgen receptor: evidence for an alternative DNA-dependent dimerization, and an active role of sequences flanking the response element on transactivation. Biochem. J. 369 (2003) 141-151
6. Shaffer P.L., Jivan A., Dollins D.E., Cleassens F., and Gewirth D.T. Structural basis of androgen receptor binding to selective androgen response elements. PNAS 101 (2004) 4758-4763
7. Brodie J., and McEwan I.J. Intra-domain communication between the N-terminal and DNA-binding domains of the androgen receptor: modulation of androgen response element DNA binding. J. Mol. Endocrinol. 34 (2005) 603-615
8. Schoonen W.G., Vermeulen G.J., Deckers G.H., Verbost P.M., and Kloosterboer H.J. Antiprogestins: their mechanisms of action and the consequences for compound selection by in vitro and in vivo studies. Curr. Top. Steroid Res. 2 (1999) 15-54
9. Blankvoort B.M.J., De Groene E.M., Van Meeteren-Kreikamp A.P., Witkamp R.F., Rodenburg R.J.T., and Aarts J.M.M.J.G. Development of an androgen reporter gene assay (AR-LUX) utilising a human cell line with an endogenously regulated androgen receptor. Anal. Biochem. 298 (2001) 93-102
10. Willemsen P., Scippo M., Maghuin-Rogister G., Martial J.A., and Muller M. Enhancement of steroid receptor-mediated transcription for the development of highly responsive bioassays. ABC 382 (2005) 894-905
11. Sonneveld E., Riteco J.A.C., Jansen H.J., Pieterse B., Brouwer A., Schoonen W.G., and Van der Burg B. Comparison of in vitro and in vivo screening models for androgenic and estrogenic activities. Toxicol. Sci. 89 (2006) 173-187
12. Bovee T.F.H., Helsdingen J.R., Rietjens I.M.C.M., Keijer J., and Hoogenboom L.A.P. Rapid yeast estrogen bioassays stably expressing human estrogen receptors α and β, and green fluorescent protein: a comparison of different compounds with both receptor types. JSBMB 91 (2004) 99-109
13. Schrodinger: Glide version 4.0 and Prime version 1.5, LLC, New York, 2005.
14. Sack J.S., Kish K.F., Wang C., Attar R.M., Kiefer S.E., An Y., Wu G.Y., Scheffler J.E., Salvati M.E., Krystek Jr. S.R., Weinmann R., and Einspahr H.M. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 4904-4909
15. Lyne P.D., Lamb M.L., and Saeh J.C. Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. J. Med. Chem. 49 (2006) 4805-4808
16. Bovee T.F.H., Helsdingen J.R., Hamers A.R.M., Duursen M.B.M., Nielen M.W.F., and Hoogenboom L.A.P. A new highly specific and robust yeast androgen bioassay for the detection of agonists and antagonists. Anal. Bioanal. Chem. 389 (2007) 1549-1558
17. NIH Publication No: 03-4503, ICCVAM Evaluation of In Vitro Methods for Detecting Potential Endocrine Disruptors, 2003.
18. Collins D.C. The role of hormonal contraceptives: sex hormone receptor binding, progestin selectivity, and the new oral contraceptives. Am. J. Obstet. Gynecol. 170 (1994) 1508-1513
19. Fuhrman U., Krattenmacher R., Slater E.P., and Fritzmeier K.H. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 54 (1996) 243-251
20. Hoogenboom L.A.P., De Haan L., Hooijerink D., Bor G., Murk A.J., and Brouwer A. Estrogenic activity of estradiol and its metabolites in the ER-CALUX assay with human T47D breast cells. APMIS 109 (2001) 101-107
21. Donova M.V., Egorova O.V., and Nikolayeva V.M. Steroid 17β-reduction by microorganisms-a review. Process Biochem. 40 (2005) 2253-2262
22. Rizner T.L., and Zakelj-Mavric M. Characterization of fungal 17beta-hydroxysteroid dehydrogenases. Comp. Biochem. Physiol. Biochem. Mol. Biol. 127 (2000) 53-63
23. Waller C.L., Juma B.W., Gray L.E., and Kelce W.R. Three-dimensional quantitative structure-activity relationships for androgen receptor ligands. Toxicol. Appl. Pharmacol. 137 (1996) 219-227
24. Fang H., Tong W., Branham W.S., Moland C.L., Dial S.L., Hong H., Xie Q., Perkins R., Owens W., and Sheehan D.M. Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor. Chem. Res. Toxicol. 16 (2003) 1338-1358
25. Dhooge W., Arijs K., D'Haese I., Stuyvaert S., Versonnen B., Janssen C., Verstaete W., and Comhaire F. Experimental parameters affecting sensitivity and specificity of a yeast assay for estrogenic compounds: results of an interlaboratory validation exercise. Anal. Bioanal. Chem. 386 (2006) 1419-1428
26. Bourguet W., Germain P., and Gronemeyer H. Nuclear receptor ligand-binding domains: 3D structures, molecular interactions and pharmacological implications. Trends Pharmacol. Sci. 21 (2000) 381-388
27. Zhang X., Li X., Allan G.F., Musto A., Lundeen S.G., and Sui Z. Discovery of indole-containing tetracycles as a new scaffold for androgen receptor ligands. Bioorg. Med. Chem. Lett. 16 (2006) 3233-3237
28. Gao W., Bohl C.E., and Dalton J.T. Chemistry and structural biology of androgen receptor. Chem. Rev. 105 (2005) 3352-3370
29. Callewaert L., Van Tilborgh N., and Claessens F. Interplay between two hormone-independent activation domains in the androgen receptor. Cancer Res. 66 (2006) 543-553
30. Jaaskelainen J., Deeb A., Schwabe J.W., Mongan N.P., Martin H., and Hughes I.A. Human androgen receptor gene ligand-binding-domain mutations leading to disrupted interaction between the N- and C-terminal domains. J. Mol. Endocrinol. 36 (2006) 361-368
31. Kazmin D., Prytkova T., Cook C.E., Wolfinger R., Chu T.M., Beratan D., Norris J.D., Chang C.Y., and McDonnell D.P. Linking ligand-induced alterations in androgen receptor structure to differential gene expression: a first step in the rational design of selective androgen receptor modulators. Mol. Endocrinol. 20 (2006) 1201-1217
32. Georget V., Bourgeut W., Lumbroso S., Makni S., Sultan C., and Nicolas J.C. Glutamic acid 709 substitutions highlight the importance of the interaction between androgen receptor helices H3 and H12 for androgen and antiandrogen actions. Mol. Endocrinol. 20 (2006) 724-734
33. Matias P.M., Donner P., Coelho R., Thomaz M., Peixoto C., Macedo S., Otto N., Joschko S., Scholz P., Wegg A., Bäsler S., Schäfer M., Egner U., and Carrondo M.A. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J. Biol. Chem. 275 (2000) 26164-26171
34. Attardi B.J., Hild S.A., and Reel J.R. Diemethandrolone undecanoate: a new potent orally active androgen with progestational activity. Endocrinology 147 (2006) 3016-3026
35. Pereira de Jésus-Tran K., Côté P., Cantin L., Blanchet J., Labrie F., and Breton R. Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Sci. 15 (2006) 987-999